Document is current
Any future updates will be listed below
-
Authors
Zebley, Caitlin C. https://orcid.org/0000-0002-8419-4660
Zehn, Dietmar https://orcid.org/0000-0003-1393-8527
Gottschalk, Stephen https://orcid.org/0000-0003-3991-7468
Chi, Hongbo https://orcid.org/0000-0002-9997-2496
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA279926-01, CA253188, CA281868)
American Lebanese Syrian Associated Charities
Alex Lemonade Stand Young Investigator Grant
Deutsche Forschungsgemeinschaft (SFB1371, ZE 832/6-1, ZE 832/8-1)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI105887, AI131703, AI150241, AI150514, Al140761)
- License Information
-
More Information
Article History
Received: 12 April 2024
Accepted: 12 June 2024
First Online: 18 July 2024
Competing interests
: C.C.Z. declares patents related to epigenetic biomarkers and methods for enhancing CAR T cell function. S.G. is co-inventor on patents or patent applications in the fields of T cell and gene therapy for cancer, is a member of the scientific advisory board of Be Biopharma and CARGO and the Data and Safety Monitoring Board of Immatics and has received honoraria from Tessa Therapeutics within the last year. H.C. is a co-inventor on patents or patent applications in the field of immunotherapy and consults or consulted for Kumquat Biosciences, Chugai Pharmaceuticals, Ono Pharmaceutical and TCura Bioscience. D.Z. does not declare any competing interests.
